Jun 17 2010
BioNeutral Group, Inc. (OTCBB:BONU), a specialty chemical technology-based life science company, announced today that in collaboration with Steri-7™, a UK-based specialty chemical health care company, it will be expanding availability of its sporicidal formulations in the UK, Europe and the Middle East. Steri-7™ recently obtained approval from the UK's National Health Service (NHS) to market its formulations as a sporicidal cleaner/wipe.
“To my knowledge, there is no other approved product that both addresses difficult-to-kill spores such as C. difficile and is approved by the NHS. The high-level disinfection wipes market is quickly growing in the UK and Europe and is estimated at 100 million pounds per year.”
BioNeutral has concluded testing for an application to the Environmental Protection Agency (EPA). If and when received, BioNeutral anticipates this approval will facilitate entry into the North American and South American markets as well as complementary markets worldwide. Steri-7™ now has over 20 distributors within the broader healthcare market. In May 2010, BioNeutral entered into a non-binding Head of Terms letter setting forth a plan to acquire all of the shares of Steri-7™. The acquisition is subject to negotiation of a definitive acquisition agreement, satisfactory completion of due diligence, completion of a specified financing transaction by BioNeutral, and other customary terms and conditions. Terms and conditions are being held confidential pending execution of a definitive agreement.
James Fraser, Chief Executive Officer of Steri-7™, said, "It has taken two years to meet all of the exhaustive test requirements for NHS approval as a sporicidal cleaner/wipe to help eliminate MRSA, C. difficile, and other dangerous and life-threatening healthcare-acquired infections. Approval by the NHS (approval #VJT 183, 184, 185) is essential for distribution throughout the healthcare sector, including hospitals and nursing homes, in the UK, as is EPA approval in the US. We believe a combined BioNeutral/Steri-7™ product line will meet the requirements in all major markets around the world."
Mr. Fraser continued, "Steri-7™ has been approved by the Air Ambulance Service, and our company has recently received ISO 13485 approval status, which represents the highest standard set by the International Organization for Standardization. Only products made to this level may use the CE mark for surgical instrument cleaners that facilitates entry to European countries."
Nick Sayer, Worldwide Director of Sales and Marketing for Steri-7™, added, "To my knowledge, there is no other approved product that both addresses difficult-to-kill spores such as C. difficile and is approved by the NHS. The high-level disinfection wipes market is quickly growing in the UK and Europe and is estimated at 100 million pounds per year."
Empowering lived experience in healthcare research